Abstract:Rationale: microRNAs (miRNAs) are frequently deregulated and play important roles in the pathogenesis and progression of acute myeloid leukemia (AML). miR-182 functions as an onco-miRNA or tumor suppressor miRNA in the context of different cancers. However, whether miR-182 affects the self-renewal of leukemia stem cells (LSCs) and normal hematopoietic stem progenitor cells (HSPCs) is unknown. Methods: Bisulfite sequencing was used to analyze the methylation status at pri-miR-182 promoter. Lineage-negative HSPCs were isolated from miR-182 knockout (182KO) and wild-type (182WT) mice to construct MLL-AF9-transformed AML model. The effects of miR-182 depletion on the overall survival and function of LSC were analyzed in this mouse model in vivo. Results: miR-182-5p (miR-182) expression was lower in AML blasts than normal controls (NCs) with hypermethylation observed at putative pri-miR-182 promoter in AML blasts but unmethylation in NCs. Overexpression of miR-182 inhibited proliferation, reduced colony formation, and induced apoptosis in leukemic cells. In addition, depletion of miR-182 accelerated the development and shortened the overall survival (OS) in MLL-AF9-transformed murine AML through increasing LSC frequency and self-renewal ability. Consistently, overexpression of miR-182 attenuated AML development and extended the OS in the murine AML model. Most importantly, miR-182 was likely dispensable for normal hematopoiesis. Mechanistically, we identified BCL2 and HOXA9 as two key targets of miR-182 in this context. Most importantly, AML patients with miR-182 unmethylation had high expression of miR-182 followed by low protein expression of BCL2 and resistance to BCL2 inhibitor venetoclax (Ven) in vitro. Conclusions: Our results suggest that miR-182 is a potential therapeutic target for AML patients through attenuating the self-renewal of LSC but not HSPC. miR-182 promoter methylation could determine the sensitivity of Ven treatment and provide a potential biomarker for it.

miR‑107 promotes the erythroid differentiation of leukemia cells via the downregulation of Cacna2d1.

Downregulation of Mir-142 Promotes Leukemia Growth in Philadelphia Chromosome-Positive (ph+) Acute Lymphoblastic Leukemia (ALL): A Possible Novel Therapeutic Target?

Profiling of Micrornas in Aml Cells Following Overexpression or Silencing of the Vegf Gene

MicroRNA-181a-mediated Downregulation of AC9 Protein Decreases Intracellular Camp Level and Inhibits ATRA-induced APL Cell Differentiation

Mir-22 Has a Potent Anti-Tumour Role with Therapeutic Potential in Acute Myeloid Leukaemia

Mir-302 Cluster Inhibits Angiogenesis and Growth of K562 Leukemia Cells by Targeting VEGFA.

Downregulation of miR-142a Contributes to the Enhanced Anti-Apoptotic Ability of Murine Chronic Myelogenous Leukemia Cells

CRKL but not CRKII contributes to hemin‐induced erythroid differentiation of CML

Mir-638 Regulates Differentiation and Proliferation in Leukemic Cells by Targeting Cyclin-dependent Kinase 2*

MiR-107 suppresses cell proliferation and tube formation of Ewing sarcoma cells partly by targeting HIF-1β

Circulating Exosomal MiR-107 Restrains Tumorigenesis in Diffuse Large B-Cell Lymphoma by Targeting 14-3-3η

The synergistic effect of miR-203 and cytarabine on the inhibition of cell proliferation and induction of apoptosis in chronic myelogenous leukemia cells

Aberrant Microrna Expression in Chinese Patients with Chronic Lymphocytic Leukemia.

CLPs-miR-103a-2-5p inhibits proliferation and promotes cell apoptosis in AML cells by targeting LILRB3 and Nrf2/HO-1 axis, regulating CD8 + T cell response

MiR-424 Regulates Monocytic Differentiation of Human Leukemia U937 Cells by Directly Targeting CDX2

miR-107 Targets NSG1 to Regulate Hypopharyngeal Squamous Cell Carcinoma Progression through ERK Pathway

Cat104 Silence Behaves As A Tumor Suppressor In Human Leukemia Cells By Down Regulating Mir-182 Expression

Identification and functional characterization of the miRNA-gene regulatory network in chronic myeloid leukemia lineage negative cells

RETRACTED ARTICLE: MiR-362-5p Promotes the Malignancy of Chronic Myelocytic Leukaemia Via Down-Regulation of GADD45α

DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclax

CircPLXNB2 regulates acute myeloid leukemia progression through miR-654-3p/CCND1 axis